Oncocyte Corp Stock Performance
| OCX Stock | USD 2.08 0.02 0.95% |
The company holds a Beta of 0.18, which implies not very significant fluctuations relative to the market. As returns on the market increase, OncoCyte Corp's returns are expected to increase less than the market. However, during the bear market, the loss of holding OncoCyte Corp is expected to be smaller as well. At this point, OncoCyte Corp has a negative expected return of -0.6%. Please make sure to check OncoCyte Corp's maximum drawdown, as well as the relationship between the daily balance of power and period momentum indicator , to decide if OncoCyte Corp performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days OncoCyte Corp has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's fundamental indicators remain fairly strong which may send shares a bit higher in February 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return (1.89) | Five Day Return (5.45) | Year To Date Return (10.73) | Ten Year Return (98.71) | All Time Return (98.71) |
Last Split Factor 1:20 | Last Split Date 2023-07-25 |
1 | Disposition of 3564728 shares by Gutfreund John Peter of OncoCyte Corp at 1.53 subject to Rule 16b-3 | 11/05/2024 |
2 | OncoCyte Corporation Q3 2024 Earnings Call Transcript | 11/13/2024 |
3 | OncoCyte Given Buy Rating at Needham Company LLC | 11/14/2024 |
4 | Oncocyte dd-cfDNA Assay Detects Kidney Transplant Rejection 11 | 12/02/2024 |
5 | Acquisition by Gutfreund John Peter of 705000 shares of OncoCyte Corp at 0.3544 subject to Rule 16b-3 | 12/03/2024 |
6 | Oncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New Study | 12/04/2024 |
7 | Acquisition by Andrea James of 20000 shares of OncoCyte Corp at 2.29 subject to Rule 16b-3 | 12/05/2024 |
8 | Acquisition by Andrea James of 200000 shares of OncoCyte Corp at 2.87 subject to Rule 16b-3 | 12/06/2024 |
9 | Oncocyte corp CFO James Andrea acquires 45,800 in stock | 12/09/2024 |
10 | Acquisition by Andrew Arno of 12500 shares of OncoCyte Corp at 2.108 subject to Rule 16b-3 | 12/26/2024 |
11 | Andrew Arno Purchases 12,500 Shares of OncoCyte Co. Stock | 12/27/2024 |
12 | Oncocyte Expands Market Opportunity for VitaGraft Kidney | 01/06/2025 |
13 | Oncocyte names Paul Billings as consulting chief medical officer | 01/08/2025 |
14 | Acquisition by Smith Patrick W of 5669 shares of OncoCyte Corp at 2.08 subject to Rule 16b-3 | 01/13/2025 |
15 | Acquisition by Smith Patrick W of 100 shares of OncoCyte Corp at 2.08 subject to Rule 16b-3 | 01/14/2025 |
16 | FNY Investment Advisers LLC Buys 6,481 Shares of OncoCyte Co. | 01/15/2025 |
| Begin Period Cash Flow | 23.2 M |
OncoCyte |
OncoCyte Corp Relative Risk vs. Return Landscape
If you would invest 312.00 in OncoCyte Corp on October 20, 2024 and sell it today you would lose (104.00) from holding OncoCyte Corp or give up 33.33% of portfolio value over 90 days. OncoCyte Corp is generating negative expected returns assuming volatility of 3.4309% on return distribution over 90 days investment horizon. In other words, 30% of stocks are less volatile than OncoCyte, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
OncoCyte Corp Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for OncoCyte Corp's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as OncoCyte Corp, and traders can use it to determine the average amount a OncoCyte Corp's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1737
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | OCX |
Estimated Market Risk
| 3.43 actual daily | 30 70% of assets are more volatile |
Expected Return
| -0.6 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.17 actual daily | 0 Most of other assets perform better |
Based on monthly moving average OncoCyte Corp is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of OncoCyte Corp by adding OncoCyte Corp to a well-diversified portfolio.
OncoCyte Corp Fundamentals Growth
OncoCyte Stock prices reflect investors' perceptions of the future prospects and financial health of OncoCyte Corp, and OncoCyte Corp fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on OncoCyte Stock performance.
| Return On Equity | -1.65 | ||||
| Return On Asset | -0.19 | ||||
| Operating Margin | (55.43) % | ||||
| Current Valuation | 35.98 M | ||||
| Shares Outstanding | 16.84 M | ||||
| Price To Earning | (12.20) X | ||||
| Price To Book | 3.64 X | ||||
| Price To Sales | 49.86 X | ||||
| Revenue | 1.5 M | ||||
| Gross Profit | 116 K | ||||
| EBITDA | (23.12 M) | ||||
| Net Income | (27.78 M) | ||||
| Cash And Equivalents | 45.41 M | ||||
| Cash Per Share | 0.38 X | ||||
| Total Debt | 2.87 M | ||||
| Debt To Equity | 0.05 % | ||||
| Current Ratio | 3.49 X | ||||
| Book Value Per Share | 0.71 X | ||||
| Cash Flow From Operations | (23.32 M) | ||||
| Earnings Per Share | (4.40) X | ||||
| Market Capitalization | 35.35 M | ||||
| Total Asset | 74.89 M | ||||
| Retained Earnings | (289.88 M) | ||||
| Working Capital | 3.5 M | ||||
| Current Asset | 15.28 M | ||||
| Current Liabilities | 3.97 M | ||||
About OncoCyte Corp Performance
Evaluating OncoCyte Corp's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if OncoCyte Corp has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if OncoCyte Corp has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 713.88 | 749.58 | |
| Return On Tangible Assets | (1.75) | (1.83) | |
| Return On Capital Employed | (0.43) | (0.45) | |
| Return On Assets | (0.33) | (0.35) | |
| Return On Equity | (1.25) | (1.31) |
Things to note about OncoCyte Corp performance evaluation
Checking the ongoing alerts about OncoCyte Corp for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for OncoCyte Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| OncoCyte Corp generated a negative expected return over the last 90 days | |
| OncoCyte Corp has high historical volatility and very poor performance | |
| The company reported the last year's revenue of 1.5 M. Reported Net Loss for the year was (27.78 M) with profit before taxes, overhead, and interest of 116 K. | |
| OncoCyte Corp has about 45.41 M in cash with (23.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.38. | |
| Roughly 20.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from thelincolnianonline.com: FNY Investment Advisers LLC Buys 6,481 Shares of OncoCyte Co. |
- Analyzing OncoCyte Corp's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether OncoCyte Corp's stock is overvalued or undervalued compared to its peers.
- Examining OncoCyte Corp's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating OncoCyte Corp's management team can have a significant impact on its success or failure. Reviewing the track record and experience of OncoCyte Corp's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of OncoCyte Corp's stock. These opinions can provide insight into OncoCyte Corp's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for OncoCyte Stock Analysis
When running OncoCyte Corp's price analysis, check to measure OncoCyte Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OncoCyte Corp is operating at the current time. Most of OncoCyte Corp's value examination focuses on studying past and present price action to predict the probability of OncoCyte Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OncoCyte Corp's price. Additionally, you may evaluate how the addition of OncoCyte Corp to your portfolios can decrease your overall portfolio volatility.